The Evolution of Multiple Myeloma Patient Management: Managing Today, Preparing for Tomorrow

San Diego, California
Friday, November 30, 2018
The Evolution of Multiple Myeloma Patient Management: Managing Today, Preparing for Tomorrow
Friday, November 30, 2018 7:00 AM - 11:00 AM (Pacific Time)

San Diego Convention Center, Room 6CF
(619) 525-5000
111 West Harbor Drive
San Diego, California 92101
United States

Map and Directions

Join us on Friday, November 30, 2018, for a CME-certified Friday Satellite Symposium preceding the 60th American Society of Hematology (ASH) Annual Meeting and Exposition.

7:00 AM – 8:00 AM
Registration and Breakfast

8:00 AM – 11:00 AM
Scientific Program

Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers (HCPs) involved in the care of patients with multiple myeloma.

Program Overview

The clinical multiple myeloma arena has undergone significant advances in diagnosis and prognosis, minimal residual disease monitoring, and supportive care. This expansion brings renewed hope to patients, but it presents new challenges for the clinicians charged with their care. Some patients enjoy many years in clinical remission, whereas for others survival is no more than 2 or 3 years. This reflects the heterogeneity of myeloma and underscores the inappropriateness of a one-size-fits-all management approach. Improving patient outcomes requires building on the foundation of current therapies with new agents and combinations. It also requires that clinicians fully understand the nature of the disease so they can provide patients with a more personalized approach to treatment. Oncology HCPs have a growing array of tools at their disposal to favorably influence a patient’s quality and quantity of life at every stage of disease—but they can only take advantage of these tools by remaining current on the latest research and understanding the appropriate timing and strategies for using newer therapies.

Through the use of iPad-based technology developed to enhance interactivity and learner engagement, this symposium features evidence-based presentations interspersed with patient cases designed to reinforce key points. The case studies provide a practical context, helping learners integrate new information and strategies into their practices and better enabling them to assess such factors as patient profile, clinical evidence, and risk-versus-benefit in the quest to achieve the best possible durable response.

Learning Objectives
At the conclusion of this activity, participants should be better able to:
  • Incorporate the most current imaging procedures, cytogenetics, genomics, and other testing tools to define patient prognosis and risk stratification
  • Select treatment combinations in the frontline setting based on risk and patient-specific characteristics
  • Describe the advantages and limitations of measuring minimal residual disease
  • Identify patients who may benefit from consolidation and/or maintenance therapy
  • Incorporate the use of novel agent/monoclonal antibody–based regimens for relapsed/refractory patients based on currently available evidence, including patient-specific features and genomics
  • Evaluate emerging data from clinical trials on oral small-molecule inhibitors and immune-oncology–based treatment regimens
Accreditation and Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Penn State College of Medicine designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Access Statement
RedMedEd complies fully with the legal requirements of the Americans With Disabilities Act. If you are in need of special accommodation, please indicate your need in writing or contact Karen Tenaglia at 610.251.6841 or

Jointly provided by

Support for this activity has been provided through educational grants from Adaptive Biotechnologies, Amgen, and Celgene Corporation.

Contact Information

  • Karen Tenaglia, RedMedEd
    Phone: 610.251.6841
© 2019
Quick, easy and affordable online event registration and event management software for all event sizes.